Recent developments highlight Pulsenmore’s ongoing commercial expansion and product launches, including U.S. market engagements and new service offerings.

• Pulsenmore announced its full year 2025 earnings conference call scheduled in March 2026 [N1].
• The company built U.S. momentum with another commercial engagement following FDA clearance of its home ultrasound devices [N2].
• Pulsenmore announced its first commercial engagement with a leading U.S.-based medical center to provide home ultrasound services [N3].
• Pulsenmore and Clalit Health Services launched the first at-home follicular monitoring service for IVF and fertility preservation in January 2026 [N4][N5].
• Pulsenmore commenced trading on Nasdaq in January 2026 as it expanded FDA-authorized home prenatal ultrasound devices in the U.S. [N6][N7].

Pulsenmore’s recent FDA approval and Nasdaq listing mark significant milestones enabling expansion into the large U.S. prenatal care market, including underserved maternity care deserts. The company’s strategic partnerships and commercial engagements in Israel and the U.S. provide a foundation for revenue growth. Its innovative home-use ultrasound devices meet growing demand for remote healthcare solutions, telehealth integration, and patient convenience. The company’s recurring revenue model through software subscriptions and ongoing product development pipeline offer potential for diversified revenue streams. Pulsenmore’s strong intellectual property portfolio and clinical evidence supporting product efficacy enhance its market appeal and potential adoption by healthcare providers and patients.

Pulsenmore operates in a competitive and regulated medical device market where timely regulatory approvals and market acceptance are critical. The company reported a net loss in 2025 and remains in early commercialization stages outside Israel, with revenue concentration from a few strategic partners. Manufacturing relies on subcontractors, which may pose supply chain risks. Expansion into new geographies, particularly the U.S., involves execution risks including establishing partnerships and achieving adoption. The company’s financial performance depends on scaling sales and managing operating expenses. Changes in healthcare regulations, reimbursement policies, or competitive technologies could impact market penetration and profitability.

Pulsenmore’s competitive strengths include its proprietary ultrasound technology enabling reliable home-use scans, a broad patent portfolio with 31 issued patents and 63 pending applications, and established partnerships with major healthcare providers such as Clalit and Sheba in Israel. The company’s products address a unique market niche of patient-initiated home ultrasound monitoring, supported by regulatory approvals in key markets including the U.S. FDA clearance. Its experienced management team with deep ultrasound expertise and integrated hardware-software development capabilities further support its competitive positioning. The partially outsourced manufacturing model with final assembly in Israel allows scalability while maintaining quality control. These factors collectively create barriers to entry and support Pulsenmore’s market differentiation.

• Regulatory Approval and Compliance Risk: Pulsenmore’s products require regulatory approvals in multiple jurisdictions. Delays or failures in obtaining or maintaining these approvals could restrict market access.
• Commercialization and Market Adoption Risk: The company’s growth depends on successful commercialization and adoption of its products by healthcare providers and patients, particularly in new markets like the U.S.
• Supply Chain and Manufacturing Risk: Reliance on subcontractors for component manufacturing and final assembly in Israel may expose the company to supply disruptions or quality control issues.
• Financial and Operating Loss Risk: Pulsenmore reported net losses and depends on scaling revenue and managing expenses to achieve profitability.
• Competitive Risk: The medical device and home ultrasound markets are competitive with potential new entrants and alternative technologies that could affect Pulsenmore’s market share.

• Pulsenmore Ltd. is an emerging medical device company headquartered in Israel, focused on non-invasive portable ultrasound solutions for home use [S1].
• The company’s primary products include Pulsenmore ES (home prenatal ultrasound device), Pulsenmore FC (follicular monitoring for IVF and fertility preservation), and Pulsenmore MC (early development stage for pulmonary fluid monitoring) [S1].
• Pulsenmore ES is FDA approved as a Class II device in the U.S. and approved in multiple other markets including Europe (CE), Israel, Australia, Brazil, and Colombia [S1].
• Pulsenmore FC is approved in Israel and supplied for clinical research in other territories; plans exist to seek U.S. approval after gaining more real-world experience [S1].
• The company’s products enable patient self-scanning at home with telehealth integration, allowing remote monitoring and reducing clinic visits [S1].
• Pulsenmore has strategic partnerships with Clalit Health Services and Sheba Medical Center in Israel, which accounted for approximately 96% of revenue in 2025 [S1].
• In 2025, Pulsenmore supplied approximately 6,915 Pulsenmore ES units to Clalit and 110 units to Sheba for prenatal patient distribution [S1].
• The company’s revenue for the year ended December 31, 2025 was approximately $12.5 million USD, with a net loss of about $4.97 million USD [S1].
• Cash and cash equivalents as of December 31, 2025 were approximately $6.77 million USD, with a current ratio of 7.88 and a cash ratio of 2.09, indicating strong liquidity [S1].
• Pulsenmore’s manufacturing is partially outsourced with final assembly in Israel, complying with ISO 13485:2016, CE, and FDA GMP quality standards [S1].
• The company has a broad intellectual property portfolio with 31 issued patents and 63 pending patent applications as of March 15, 2026 [S1].
• Pulsenmore’s management team is experienced in ultrasound device commercialization and home-use medical devices [S1].
• The company commenced Nasdaq trading under ticker PLSM on January 21, 2026 [N6][N7][S1].
• Recent commercial engagements include agreements with two U.S.-based medical centers to provide Pulsenmore ES home ultrasound services for remote monitoring [N3][N2].
• Pulsenmore and Clalit Health Services launched the first at-home follicular monitoring service for IVF and fertility preservation in January 2026 [N4][N5].
• The company is focused on expanding its U.S. commercial footprint following FDA clearance, targeting maternity care deserts and underserved regions [S1].
• Pulsenmore’s business model in the U.S. includes recurring revenue components such as software-as-a-service clinician dashboard subscriptions, targeted to represent about 40% of revenue [S1].
• The company’s marketing strategy includes multi-channel campaigns positioning Pulsenmore ES as a practical, safe, and effective remote sonographic fetal assessment solution [S1].
• Pulsenmore’s 2025 capital expenditures were approximately $42 thousand USD, mainly for computers, software, and laboratory equipment [S1].
• There are no material legal claims against the company as of the latest financial statements [S1].
• Pulsenmore’s revenue is primarily generated from sales in Israel, with growing presence in the U.S. and other international markets [S1].
• The company’s products address a growing market driven by demand for remote-access health solutions, preventive diagnostics, and telehealth trends [S1].
• Pulsenmore’s products have demonstrated clinical impact including high scan suitability for clinical evaluation and reported reductions in pregnancy-related anxiety and hospitalizations [S1].
• The company’s recent news includes announcements of earnings conference calls and commercial engagements in the U.S. following FDA clearance [N1][N2][N3].